GSK Jemperli Gets US Approval for Advanced Rectal Cancer

MT newswire2026/10/20 08:26

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

04:26 AM EDT, 10/20/2026 (MT Newswires) -- GSK (GSK) said Monday the US Food and Drug Administration approved Jemperli for adults with microsatellite instability-high or mismatch repair deficient locally advanced rectal cancer. In a phase 2 trial of 144 patients, 68% were free of detectable cancer without surgery one year after starting treatment, and no responders saw the disease return after a median of more than two years, the company said. Standard care combines chemotherapy, radiation and surgery, which can cause lasting bowel, urinary and sexual problems, secondary cancers and infertility, and the biomarker appears in 5% to 10% of rectal cancers, GSK said. The FDA granted approval under an accelerated pathway, and serious side effects affected 20% of patients, and 3% stopped treatment permanently, it added.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Super Micro Computer has released its preliminary Q1 results for the 2027 fiscal year, projecting revenue between $18.5 billions and $19.5 billions, significantly exceeding the previous guidance of $14.0 billions to $15.5 billions and analyst consensus of $15.23 billions—an increase of approximately 27%. Gross margin is preliminarily expected to be between 12.0% and 12.5%, also higher than earlier guidance. Following the announcement, the company's share price surged 11% in after-hours trading. The company will hold its full quarterly earnings call on November 3, and final figures may be subject to adjustment.

华尔街见闻•2026/10/20 21:18